Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Anika’s Hyalofast trial failed to meet key endpoints due to missing data and dropouts, causing shares to fall 27.4% to $8.10 on July 30, 2025.
-
Anika allegedly misled on Hyalofast trial; study missed co-primary endpoints. Stock plunged 27.4% to $8.10 on July 30, 2025, hurting investors.
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or...
-
NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Nutex Health Inc....
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Portland, OR, Nov. 15, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Joint Pain Injections Market size garnered $6.3 billion in 2021, and...